Study of apitegromab for people with FSHD
Part of Bones, joints & muscles, Brain & nervous system, Genetic & congenital clinical trials.
This study tests whether a drug called apitegromab can help improve muscle function in people with facioscapulohumeral muscular dystrophy (FSHD). It is for adults aged 18-60 who have mild to moderate symptoms and can walk or run 10 meters in 5 seconds or less.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- You have a genetic diagnosis of FSHD type 1 or type 2.
- Your muscle weakness is rated as mild to moderate (score 1.5 to 3.0 on the Ricci scale).
- You can walk or run 10 meters (about 33 feet) in 5 seconds or less.
- You are not taking certain muscle-affecting medications or steroids (inhaled or topical steroids are allowed).
- You are able to undergo MRI scans (no metal implants or severe claustrophobia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental medicine called Del-brax (AOC 1020) for people with facioscapulohumeral muscular dystrophy (FSHD). The goal is to see if it can help improve muscle strength and slow the disease. You may be able to join if you have a confirmed FSHD diagnosis and can walk at least 10 meters on your own.
This trial studies how well certain physical/movement tests work in people with facioscapulohumeral muscular dystrophy (FSHD). It may help clinicians measure changes more accurately and tailor care over time.
This study tests a personalized home exercise program designed to reduce pain and fatigue in people with facioscapulohumeral muscular dystrophy (FSHD). It uses a smartphone app to guide exercises that may help you feel better.
This study tests a new medicine called SAT-3247 to see if it can safely improve muscle strength in people with facioscapulohumeral muscular dystrophy (FSHD), a condition that causes muscle weakness, especially in the face, shoulders, and legs. Participating may help you and future patients by finding a treatment that could slow or reduce muscle loss.
This study is testing a new medicine, SFL-0821, to see if it is safe and useful for people with FSHD. It may help if it works, but it is still experimental.
This study tests a new medicine called apitegromab for babies under 2 years old with spinal muscular atrophy (SMA). It looks at whether the drug can help with muscle strength and reaching motor milestones like sitting or rolling.
Hear when a new Facioscapulohumeral Muscular Dystrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.